Oncolytics Biotech stock (CA6823101073): Q4 earnings miss and upcoming report

Oncolytics Biotech reported Q4 2025 EPS of -$0.08, missing estimates by $0.02 on March 30, 2026. Shares recently gained 1.54% to $0.90. Next earnings due May 13.

Oncolytics Biotech stock has drawn attention ahead of its estimated Q1 2026 earnings on May 13, 2026, following a Q4 2025 earnings miss. The company posted an EPS of -$0.08 on March 30, 2026, below the consensus of -$0.06, according to MarketBeat as of May 2026. Shares rose 1.54% on May 11, 2026, closing at $0.90 on Nasdaq.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Oncolytics Biotech, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: Calgary, Canada
• Core markets: US, global
• Key revenue drivers: Pelareorep development
• Home exchange/listing venue: Nasdaq (ONCY)
• Trading currency: USD

Oncolytics Biotech: core business model

Oncolytics Biotech develops immuno-oncolytic viruses, primarily pelareorep, a non-pathogenic reovirus targeting solid tumors and hematological malignancies. The therapy induces tumor lysis and promotes immune responses, as described on Robinhood as of 2026. Headquartered in Calgary, Alberta, the firm has 28 employees and focuses on clinical-stage oncology assets.

Pelareorep is central to partnerships and trials, including combinations for RAS-mutant cancers. Recent durability data highlighted its potential in metastatic colorectal cancer, per industry reports in May 2026.

Main revenue and product drivers for Oncolytics Biotech

Development milestones and partnerships drive value for Oncolytics Biotech, with pelareorep in Phase 2 and 3 trials. Q4 2025 results showed trailing EPS of -$0.29 over four quarters, with net income at -$28.76 million for the period ending December 31, 2025, published March 30, 2026, via MarketBeat as of May 2026. Future EPS is projected to improve from -$0.20 to -$0.17.

Market cap stood at $104.38 million as of the latest close at $1.04, per MarketBeat data. Nasdaq listing provides US investor access to this Canadian biotech innovator.

Industry trends and competitive position

Oncolytics Biotech operates in the immuno-oncology space, where oncolytic viruses gain traction amid immunotherapy advances. Pelareorep's tumor microenvironment modulation positions it against competitors like Amgen and BioNTech in combination therapies. US market exposure via Nasdaq enhances visibility for American investors tracking biotech breakthroughs.

Why Oncolytics Biotech matters for US investors

Nasdaq-listed Oncolytics Biotech offers US investors direct exposure to innovative cancer treatments. With trials relevant to US patient populations and partnerships potentially unlocking FDA pathways, it aligns with demand for oncology biotechs amid rising cancer incidence in the US economy.

Conclusion

Oncolytics Biotech remains focused on pelareorep advancement post-Q4 2025 earnings miss, with shares showing short-term gains ahead of May 13 reporting. Nasdaq trading facilitates US investor participation in its clinical progress. Market dynamics in biotech continue to shape its path amid volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.